Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

Barco S, Voci D, Held U, Sebastian T, Bingisser R, Colucci G, Duerschmied D, Frenk A, Gerber B, Götschi A, Konstantinides SV, Mach F, Robert-Ebadi H, Rosemann T, Simon NR, Spechbach H, Spirk D, Stortecky S, Vaisnora L, Righini M, Kucher N, OVID investigators

Open source

DOI: 10.1016/s2352-3026(22)00175-2
Published: 2022 Aug
Container: The Lancet. Haematology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3026-22-00175-2,
  title = {Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.},
  author = {Barco S and Voci D and Held U and Sebastian T and Bingisser R and Colucci G and Duerschmied D and Frenk A and Gerber B and Götschi A and Konstantinides SV and Mach F and Robert-Ebadi H and Rosemann T and Simon NR and Spechbach H and Spirk D and Stortecky S and Vaisnora L and Righini M and Kucher N and OVID investigators},
  year = {2022},
  journal = {The Lancet. Haematology},
  doi = {10.1016/s2352-3026(22)00175-2},
  url = {https://doi.org/10.1016/s2352-3026(22)00175-2}
}

RIS

TY  - JOUR
TI  - Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
AU  - Barco S
AU  - Voci D
AU  - Held U
AU  - Sebastian T
AU  - Bingisser R
AU  - Colucci G
AU  - Duerschmied D
AU  - Frenk A
AU  - Gerber B
AU  - Götschi A
AU  - Konstantinides SV
AU  - Mach F
AU  - Robert-Ebadi H
AU  - Rosemann T
AU  - Simon NR
AU  - Spechbach H
AU  - Spirk D
AU  - Stortecky S
AU  - Vaisnora L
AU  - Righini M
AU  - Kucher N
AU  - OVID investigators
PY  - 2022
JO  - The Lancet. Haematology
DO  - 10.1016/s2352-3026(22)00175-2
UR  - https://doi.org/10.1016/s2352-3026(22)00175-2
ER  -

APA

S, B., D, V., U, H., T, S., R, B., G, C., D, D., A, F., B, G., A, G., SV, K., F, M., H, R., T, R., NR, S., H, S., D, S., S, S., L, V., M, R., N, K., & investigators, O. (2022). Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.. The Lancet. Haematology. https://doi.org/10.1016/s2352-3026(22)00175-2

Source records

pubmed · retrieved 2026-09-26T11:48:39.164Z